» Articles » PMID: 35865634

Emerging Roles of Long Noncoding RNAs in Breast Cancer Epigenetics and Epitranscriptomics

Overview
Specialty Cell Biology
Date 2022 Jul 22
PMID 35865634
Authors
Affiliations
Soon will be listed here.
Abstract

Breast carcinogenesis is a multistep process that involves both genetic and epigenetic changes. Epigenetics refers to reversible changes in gene expression that are not accompanied by changes in gene sequence. In breast cancer (BC), dysregulated epigenetic changes, such as DNA methylation and histone modifications, are accompanied by epitranscriptomic changes, in particular adenine to inosine modifications within RNA molecules. Factors that trigger these phenomena are largely unknown, but there is evidence for widespread participation of long noncoding RNAs (lncRNAs) that already have been linked to virtually any aspect of BC biology, making them promising biomarkers and therapeutic targets in BC patients. Here, we provide a systematic review of known and possible roles of lncRNAs in epigenetic and epitranscriptomic processes, along with methods and tools to study them, followed by a brief overview of current challenges regarding the use of lncRNAs in medical applications.

Citing Articles

Epigenetic and epitranscriptomic role of lncRNA in carcinogenesis (Review).

Dai C, Qianjiang H, Fu R, Yang H, Shi A, Luo H Int J Oncol. 2025; 66(4).

PMID: 40017127 PMC: 11900940. DOI: 10.3892/ijo.2025.5735.


LINC00899 suppresses the progression of triple-negative breast cancer via the miRNA-425/PTEN axis and is a biomarker for neoadjuvant chemotherapy efficacy.

Niu L, Bai Y, Yu M, Sun X J Cancer. 2025; 16(5):1647-1655.

PMID: 39991583 PMC: 11843232. DOI: 10.7150/jca.100619.


Cuproptosis-related lncRNAs potentially predict prognosis and therapy sensitivity of breast cancer.

Wu X, Zhang Y, Liang G, Ye H Front Pharmacol. 2023; 14:1199883.

PMID: 37529698 PMC: 10390311. DOI: 10.3389/fphar.2023.1199883.

References
1.
Zhang W, Pan T . Pseudouridine RNA modification detection and quantification by RT-PCR. Methods. 2021; 203:1-4. PMC: 8599501. DOI: 10.1016/j.ymeth.2021.05.010. View

2.
Rong D, Dong Q, Qu H, Deng X, Gao F, Li Q . mA-induced LINC00958 promotes breast cancer tumorigenesis via the miR-378a-3p/YY1 axis. Cell Death Discov. 2021; 7(1):27. PMC: 7854648. DOI: 10.1038/s41420-020-00382-z. View

3.
Sher G, Salman N, Khan A, Prabhu K, Raza A, Kulinski M . Epigenetic and breast cancer therapy: Promising diagnostic and therapeutic applications. Semin Cancer Biol. 2020; 83:152-165. DOI: 10.1016/j.semcancer.2020.08.009. View

4.
de Santiago P, Blanco A, Morales F, Marcelain K, Harismendy O, Sjoberg Herrera M . Immune-related IncRNA LINC00944 responds to variations in ADAR1 levels and it is associated with breast cancer prognosis. Life Sci. 2020; 268:118956. DOI: 10.1016/j.lfs.2020.118956. View

5.
Chimge N, Little G, Baniwal S, Adisetiyo H, Xie Y, Zhang T . RUNX1 prevents oestrogen-mediated AXIN1 suppression and β-catenin activation in ER-positive breast cancer. Nat Commun. 2016; 7:10751. PMC: 4773428. DOI: 10.1038/ncomms10751. View